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Abstract
Background: Proteomic profiling of complex biological mixtures by the ProteinChip technology of surface-
enhanced laser desorption/ionization time-of-flight (SELDI-TOF) mass spectrometry (MS) is one of the most
promising approaches in toxicological, biological, and clinic research. The reliable identification of protein
expression patterns and associated protein biomarkers that differentiate disease from health or that distinguish
different stages of a disease depends on developing methods for assessing the quality of SELDI-TOF mass spectra.
The use of SELDI data for biomarker identification requires application of rigorous procedures to detect and
discard low quality spectra prior to data analysis.
Results: The systematic variability from plates, chips, and spot positions in SELDI experiments was evaluated
using biological and technical replicates. Systematic biases on plates, chips, and spots were not found. The
reproducibility of SELDI experiments was demonstrated by examining the resulting low coefficient of variances
of five peaks presented in all 144 spectra from quality control samples that were loaded randomly on different
spots in the chips of six bioprocessor plates. We developed a method to detect and discard low quality spectra
prior to proteomic profiling data analysis, which uses a correlation matrix to measure the similarities among
SELDI mass spectra obtained from similar biological samples. Application of the correlation matrix to our SELDI
data for liver cancer and liver toxicity study and myeloma-associated lytic bone disease study confirmed this
approach as an efficient and reliable method for detecting low quality spectra.
Conclusion: This report provides evidence that systematic variability between plates, chips, and spots on which
the samples were assayed using SELDI based proteomic procedures did not exist. The reproducibility of
experiments in our studies was demonstrated to be acceptable and the profiling data for subsequent data analysis
are reliable. Correlation matrix was developed as a quality control tool to detect and discard low quality spectra
prior to data analysis. It proved to be a reliable method to measure the similarities among SELDI mass spectra
and can be used for quality control to decrease noise in proteomic profiling data prior to data analysis.
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Background
Recent advances in proteomic profiling technologies,
such as SELDI-TOF MS (Ciphergen Biosystems, Inc., Fre-
mont, CA, http://www.ciphergen.com), have allowed pre-
liminary profiling and identification of biomarkers in
biological fluids for biological, toxicological, and clinical
research [1-10]. ProteinChip technology coupled with
SELDI-TOF MS is an effective tool for the simultaneous
detection of the relative expression levels of proteins over
a wide range of molecular weights in biological samples
under different conditions. Differences in protein expres-
sion level can then be used to identify disease, differenti-
ate different stages of a disease, toxicant treatment versus
control, or different time points following toxicant treat-
ment [11-14].
Analysis of SELDI-TOF MS data presents challenges simi-
lar to those for gene expression profile analysis from
microarray technologies. Global profiling analyses strive
to identify reliable and reproducible expression patterns
that are signatures specific to each state, such as disease
versus healthy control or different experimental condi-
tions (e.g. treated with a toxicant of interest versus
untreated). The identification of biomarkers for diagnosis
or prognosis is dependent on analysis of the highly
dimensional protein expression profiles. Data must be
correctly analyzed before valid interpretation and reliable
biological conclusions to be drawn from a protein expres-
sion profiles. Analysis of poor quality, noise laden protein
expression profiles, however, will likely lead to results
lacking biological relevance. Therefore, quality assess-
ment of the protein expression profiles and determination
of reproducibility of SELDI-TOF MS experiments and pro-
files prior to data analysis is of critical importance.
Using SELDI-TOF MS coupled with protein chip technol-
ogies for biomarker development is a complicated process
that involves many steps, including sample collection and
preparation, protein chip selection and preparation,
matrix selection and application, spectral calibration,
loading sample on chip, washing away non-specifically
bound proteins, SELDI-TOF MS parameter settings, data
recording, and data pre-processing. Any of these many
steps could introduce noise, thus, adversely affecting the
quality of the experiment and the reliability of the protein
expression profile. A high degree of variability of protein
expression profiles in SELDI experiments is not infre-
quent. The coefficient of variation for absolute intensity
measures can be as high as 50–60% [15]. Scientists have
recently realized that quality control (QC) is an important
issue in SELDI experiments and several efforts have been
made to apply some QC techniques to improve the repro-
ducibility of SELDI profiling data [3,16,17]. For example,
QC samples that are pooled from multiple samples have
been used to assess the reproducibility of a SELDI experi-
ment [18-20], while technical replicates have been used to
assess the reproducibility within the same samples [21].
Because of the complex nature of SELDI-TOF MS – Pro-
teinChip experiments, even with experimental QC, the
resultant data must be subjected to stringent quality
assessment prior to data analysis. Specifically, low quality
spectra should be identified and eliminated from analysis
to ensure the reliability of biomarkers and the associated
patterns discovered during analysis. For example, system-
atic variability in experiments may introduce additional
error sources into the data and this possibility should be
examined prior to data analysis.
We investigated systematic variability for plates, chips,
and spot positions in two independent SELDI biomarker
studies. All peaks (five in our study) appearing in all QC
samples should be used to assess the reproducibility of
experiments as recommended by Ciphergen because
those peaks are the common proteins for the QC samples
and should be in similar levels of expression. The high
level of reproducibility of our experiments was demon-
strated by low coefficients of variation for the five peaks
that appeared in all 144 spectra from QC samples. No sys-
tematic bias in the experiments was detected (there is no
single source of variation that is consistent when switch-
ing samples between spots, plates and chips). To identify
spectra of low quality, a Pearson correlation matrix was
developed as a QC tool to detect low quality spectra in
SELDI profiling data analysis, using all peaks in all spec-
tra. The rationale behind the use of a correlation matrix as
a QC tool is the assumption that protein expression pro-
files from biological replicates and technical replicates
should be similar. Thus, the correlation matrix is a meas-
ure of the similarities among the spectra and useful for
quantifying how consistently the experiments have been
conducted. We applied the correlation matrix to the
SELDI data from the study of biomarkers for liver cancer
and liver toxicity, as well as myeloma-associated lytic
bone disease. We found that the correlation matrix was an
efficient and reliable means to detect low quality spectra
should be removed. Doing so should result in more relia-
ble biomarker identification in the final protein expres-
sion profiles.
Methods
Samples
Liver cancer and liver toxicity study
Quality control samples. Plasma was collected in Li-
Heparin tubes from two individuals (one male, one
female, one Caucasian, one Oriental). Following isolation
of plasma from whole blood, all tubes were pooled,
mixed, aliquoted into eppendorf tubes, and stored frozen
at -80°C. Each tube contained between 80–100 µl of
plasma. Four tubes were used for each 96 well plate, oneBMC Bioinformatics 2005, 6(Suppl 2):S5
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spot per chip. Once thawed, the remaining sample was
discarded.
Myeloma-associated lytic bone disease
Sera from 64 newly diagnosed myeloma patients were col-
lected during routine clinic visit (Institutional Review
Board approved and signed informed consents are kept
on record). 36 samples were from patients with 1 to 26
lytic bone lesions, determined by X-ray skeletal surveys,
and 28 from patients with no evidence of lytic bone dis-
ease
SELDI protein profiling
Liver cancer and liver toxicity study: The plasma samples
were analyzed by SELDI-TOF MS on a Ciphergen Protein-
Chip Biology System II (PBS II). Specifically, 10 µl of
unfractionated samples were used in duplicate for the
nonfractionated analyses and 20 µl was used for the frac-
tionation step. Unfractionated and fractionated samples
were examined on a weak cation exchange chip (CM10).
Two solubilization steps were used for each of the samples
whether or not fractionation was to be performed: 9 M
urea, 2% CHAPS, 50 µM Tris, pH 9; and 1 M urea, 0.22%
CHAPS, 50 µM Tris, pH9. In addition, each of the plasma
samples was fractionated for analysis. The plasma to be
fractionated was subjected to anion exchange chromatog-
raphy with stepwise pH elution into 6 fractions [23], each
of these fractions was analyzed on a CM10 chip. Plasma
(20 µl) was centrifuged for 10 minutes and mixed with the
chaotropic urea/CHAPS denaturing and solubilization
buffer (30 µl). Each sample was run in duplicate.
Sinapinic acid (SPA) was used as the matrix for each sam-
ple. The chips were read at two different laser energies to
permit ionization and visualization of proteins.
Myeloma-associated lytic bone disease: The serum sam-
ples were analyzed by SELDI-TOF MS on a Ciphergen PBS
II, using IMAC30 ProteinChips (Ciphergen Biosystems,
Inc.) activated with CuSO4 according to Ciphergen's pro-
tocols. All sera were assayed in quadruplicate and posi-
tioned on the 96 spots on each of the 12 chips in a
bioprocessor to allow for variability between spots to be
determined. For consistency, a BioMek 2000 liquid-han-
dling robot (Beckman-Coulter, Fullerton, CA) was used.
SPA was the energy-absorbing matrix. Proteins above
1000 Kda m/z were interrogated using an average of 66
laser shots with laser intensity of 195 and sensitivity of 8.
Low molecular weight (MW) standards were assayed with
each run (12 chips/run). Calibrations were done for each
run.
Spectral processing
The raw SELDI mass spectra were pre-processed prior to
subsequent analysis of the expression profiles. Ciphergen
Express 2.0 software was used to calibrate all the spectra in
the myeloma-associated lytic bone disease study. Normal-
ization by Total Ion Current was applied to all spectra in
both the liver cancer and liver toxicity study and the mye-
loma-associated lytic bone disease study to minimize the
variability in spectra obtained from different times using
Ciphergen ProteinChip 3.2 software. The normalization
process took the Total Ion Current used for all the spots,
averaged the intensity, and adjusted the intensity scales
for all the spots so that all spectra could be displayed on
the same scale. Baseline subtraction was conducted prior
to normalization, as recommended by Ciphergen. Base-
line subtraction offsets in the spectra were the result of
both electrical noise and the noise from Energy Absorbing
Molecules (EAM). The lowest spectral amplitude was
detected and then was used to correct the peak height and
area. The Biomarker Wizard function in Ciphergen Pro-
teinChip 3.2 software was used to autodetect the peaks
present in all of the spectra. The spectral region from 0 to
2500 Da is unreliable for both normalization and peak
detection due to matrix interference and was therefore not
included in the analysis. A signal to noise ratio greater
than 5 was used for the first pass selection of peaks and
signal to noise ratio greater than 3 was used for the second
pass. Cluster mass window of 0.3% was used for both
studies. A requirement to be in a minimum of 100% of
samples was set for clusters generation for quality control
samples used in liver cancer and liver toxicity study
because the common proteins were expected to be
expressed in all of the samples. In myeloma-associated
lytic bone disease study the requirement was set to be in a
minimum of 5% samples for clusters generation because
different patient samples were assayed and different pro-
tein expressions for different patients were expected.
Data analysis
After spectral pre-processing using ProteinChip 3.2 soft-
ware, data was exported as a profile matrix with rows rep-
resenting spectra and columns representing peak
intensities. Principal component analysis (PCA) was per-
formed using Spotfire DecisionSite 7.1 software (Somer-
ville, MA, http://www.spotfire.com). Pearson correlation
matrix and other statistical calculations were performed
with JMP 5.1 software http://www.jmp.com. Heat maps
and correlation matrix surfaces were created with DMVS
2.0 software (Shenzhen Chipscreen Biosciences, Ltd,
Shenzhen, P. R. China, http://www.chipscreen.com).
Results
Assessment of systematic variability from plates, chips, and 
spots
SELDI-TOF MS is widely used to profile protein expres-
sion in clinical samples including from diseased versus
healthy individuals. Analysis of the profiles aims to extract
protein biomarkers from the associated patterns that dif-
ferentiate one group from another. To ensure that the var-BMC Bioinformatics 2005, 6(Suppl 2):S5
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iation in spectra reflects differences between samples
rather than systematic variability, assessment of the varia-
bility across different plates, chips, and spot positions in
protein chips is necessary and important. In our SELDI
studies of liver cancer, liver toxicity and lytic bone disease,
plasma and sera from patients and controls were applied
to the 96 spots on 12 chips on each of the six bioprocessor
plates, and the chips read on the PBSII ProteinChip reader
(whole data set not shown here). In order to evaluate the
systematic variability between plates, chips, and spots, as
well as to assess the experiment quality and reproducibil-
ity, QC samples were used. Specifically, multiple plasma
samples were pooled and used as biological replicates.
144 QC samples were randomly placed on spots of the 12
chips used for each of the six bioprocessor plates. SELDI-
TOF MS was then applied to the samples to record the
mass spectra. Spectra were first normalized using total ion
current (total protein read), and then peaks within a
molecular weight range of 2,000 to 40,000 Da were
detected and extracted. The peaks present in the spectra of
all 144 samples were then used for further analysis. These
peaks were expected to be the common proteins or pep-
tides in the QC samples. Principal component analysis
(PCA) [22], which is widely employed in signal process-
ing, statistics and neural computing to examine the maxi-
mum variability in a highly dimensional data, was used to
investigate the source of variance. The PCA results are pre-
sented in Fig. 1.
Fig. 1A shows PCA results for data points representing
spectra of the 144 QC samples with color denoting bio-
processor plate. The dispersion of the points and lack of
clustering indicates that variability across plates is ran-
dom. Fig. 1B similarly shows the PCA results for all 144
QC samples with color denoting one of the eight different
spot positions. Again, dispersion and lack of grouping
indicates the absence of systematic variability across posi-
tion. Fig. 1C similarly shows the PCA results for all 144
QC samples with color denoting each of the 12 chips used
in the six bioprocessor plates. Again there is no apparent
systematic variance. Thus, no systematic variability across
plates, across chips or the spot positions is discernable
from PCA analysis.
The samples of interest in our studies (i.e., the study of
biomarkers for liver cancer and liver toxicity, as well as
myeloma-associated lytic bone disease) were loaded on
the spots of the chips in the bioprocessor plates together
with the QC samples. As the analysis of the QC samples
showed no systematic variability across spot locations,
chips and plates, these sources of variability should have
minimum affect on the data analysis for the identification
of potential biomarkers that differentiate liver cancer
patients from the healthy individuals and patients with
bone lesions from those without bone lesions. Thus, the
biomarkers and the associated patterns in our study were
identified from the protein profiles with little systematic
variability (results not shown).
Assessment of reproducibility of experiments
Identification of systematic variability that introduces
noise by affecting the quality of peaks is but one aspect of
quality assessment of experiments. Minimal systematic
variability is a necessary but insufficient prerequisite to
conclude that the quality of the experiment is high and
acceptable. Another crucial aspect of quality assessment
for experiments is the reproducibility: the measurement of
how consistent the results are from the same or similar
samples. Biological and technical replicates were used in
the SELDI experiments of liver cancer and liver toxicity, as
well as myeloma-associated lytic bone disease studies for
the purpose of quality control and quality assessment. The
reproducibility of 144 spectra from the QC samples
assayed on six bioprocessor plates with 12 protein chips
each is shown in Fig. 2. Fig. 2A gives the average intensity
and corresponding standard deviation of the five m/z
peaks detected in all 144 spectra. The intensities of com-
mon m/z peaks show small variations. Fig. 2B gives the
coefficient of variation of the five peaks, which are all less
than 20%, indicating that the SELDI experiments are con-
sistent based on the levels of common proteins expressed
in the 144 QC samples. The analysis of the consistency of
the experiments demonstrated that high reproducibility
was obtained in our SELDI studies.
Detection of low quality spectra
The reproducibility of experiments measures the overall
consistency among a set of spectra obtained from SELDI
experiments. However, it does not give any detail on the
quality of individual spectra in the dataset. In other
words, reproducibility is a good assessment of the overall
consistency of a set of experiments, but it can not be used
to identify low quality spectra. Low quality spectra need to
be removed from the data set prior to analysis in order to
reliably discover biomarker proteins and the associated
expression patterns that differentiate a disease from con-
trol or that distinguish different stages of a disease such as
cancer. For assessment of reproducibility, all common
peaks have to be (and were) used. But for quality assess-
ment, whole spectra (all possible peaks) must to be used.
A Pearson correlation matrix was used for QC of the indi-
vidual spectra of biological and technical replicates prior
to SELDI data analysis. The rationale behind the approach
is to assume that the protein expression profiles of biolog-
ical and technical replicates of a sample are similar and
thus that the correlation among spectra of same or similar
samples should be very high.
In our liver cancer and liver toxicity studies, the biological
replicates of QC samples were used for both quality con-BMC Bioinformatics 2005, 6(Suppl 2):S5
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Assessment of systematic variability across plates, chips, and spots using principal component analysis (PCA) on the 144 quality  control samples used in the liver cancer and liver toxicity study Figure 1
Assessment of systematic variability across plates, chips, and spots using principal component analysis (PCA) 
on the 144 quality control samples used in the liver cancer and liver toxicity study. The 144 spectra obtained from 
assays of quality control samples from the liver cancer and liver toxicity study were first normalized. The five peaks which 
appeared in all 144 spectra were taken as the common proteins and used for PCA analysis using software Spotfire DecisionSite 
7.1 (Somerville, MA, http://www.spotfire.com). (A) The PCA results were color coded for the six Ciphergen bioprocessor 
plates used to assay the samples. The points represent the spectra and are spread randomly throughout the space. The spectra 
from each plate did not group together indicating a lack of systematic variability. (B) The PCA results were color coded for 
spot position. Each protein chip has eight spots. The spectra obtained from samples loaded on any same spot position can not 
be grouped together and randomly spread around in the PCA figure. Thus, spot position did not introduce systematic variabil-
ity in the data. (C) The PCA results were color coded for the chip number in which each sample was loaded for SELDI analysis. 
Total 12 chips were used for one bioprocessor plate. The spectra of samples from any chips were not grouped together in the 
PCA, but rather were spread randomly in the space, indicating a lack of systematic variability due to the chip used to assay sam-
ples.BMC Bioinformatics 2005, 6(Suppl 2):S5
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trol and quality assessment. The correlation matrix of 144
spectra obtained from SELDI experiments of QC samples
based on the five m/z peaks common to all 144 spectra is
shown as a heat map in Fig. 3. The color red in Fig. 3
denotes high correlation (r > 0.9) between two spectrums,
whereas green denotes low correlation (r < 0.9), and black
denotes r = near 0.9. The preponderance of red in Fig. 3
indicates that most of the 144 spectra are well correlated
with a few exceptions that are shown in green. In fact, the
median correlation coefficient was 0.96, with a maximum
of 1 and a minimum of -0.14. The standard deviation
within the correlation matrix was 0.13.
There are several low correlations in the matrix that were
expected to be high since all the spectra were obtained
from biological replicates of QC samples. These QC sam-
ples should have similar protein expression patterns and
therefore should be highly correlated SELDI spectra. Low
correlations are likely associated with low quality spectra
that may be caused in one or more steps in the compli-
cated SELDI experiment and must be discarded prior to
further data analysis. To confirm that the spectra with low
scores in the correlation matrix are true low quality spec-
tra, which are different from the majority of the 144 QC
Heat map of correlation matrix of the 144 spectra from qual- ity control samples Figure 3
Heat map of correlation matrix of the 144 spectra 
from quality control samples. The Pearson product-
moment correlation coefficient (R) is a measure of the 
degree of linear relationship between two spectra. A higher 
correlation indicates a more similar protein expression pat-
tern between two samples for the two spectra. Each row and 
column in the heat map of the correlation matrix represents 
a spectrum. Each point is a Pearson correlation coefficient, R, 
between the spectrum in the column and the spectrum in the 
row. The correlation coefficients were colored by the values 
of R. The higher the value of R, the brighter red is the data 
point. The lower the value of R, the brighter green is the data 
point. All 144 data points in one row (same for column) rep-
resent the correlation of one spectrum to all other spectra. 
Therefore, the green line indicates the spectrum does not 
correlate well to other spectra. The correlation matrix was 
calculated using software JMP 5.1 http://www.jmp.com and 
the heat map was created using the software DMVS 2.0 
(Shenzhen Chipscreen Biosciences, Ltd, Shenzhen, P. R. 
China, http://www.chipscreen.com)
Demonstration of reproducibility of the SELDI experiments  in liver cancer and liver toxicity study Figure 2
Demonstration of reproducibility of the SELDI 
experiments in liver cancer and liver toxicity study. 
The reproducibility of SELDI experiments was measured by 
the consistency of expression levels (peak intensities in spec-
tra) of the five common proteins appearing in all 144 quality 
control samples used in the liver cancer and liver toxicity 
study. The numbers on the x-axes are the m/z values of 
peaks (in KDa.). (A) The average intensities of the five peaks 
in the 144 spectra are represented by the blue cylinders and 
the corresponding standard deviations depicting the varia-
tions in the 144 spectra are shown in red cylinders. (B) The 
coefficient of variation (CV), which is used to measure the 
precision of the peak intensity common in the 144 spectra 
from the set of SELDI experiments, is depicted as blue cylin-
ders. All CVs are less than 0.2, which is considered accepta-
ble reproducibility in SELDI.
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samples assayed by SELDI, the raw spectra were visually
inspected. We found that the spectra detected as low qual-
ity spectra in the correlation matrix are indeed different
from the others, though the number of such spectra is very
small. Fig. 4 compares the low quality spectra (red) with
high quality spectra (blue). It can be seen clearly that all
high quality spectra are very similar to each other based
on the m/z peak patterns, but that the low quality spectra
have different m/z peak patterns compared with the high
quality spectra. The protein expression pattern observed
in the low quality spectra is distinct from the rest of the
samples although they should have similar protein
expression patterns. From the point of view of data analy-
sis those low quality spectra need to be removed prior to
Representative examples of SELDI spectra from quality con- trol samples Figure 4
Representative examples of SELDI spectra from 
quality control samples. Examples of spectra illustrate dif-
ferences between highly consistent spectra and low quality 
spectra. The spectra in blue are examples of the highly con-
sistent spectra, which include the majority of the 144 quality 
control samples. All spectra have very similar peak patterns 
as could be expected for the biological replicates of quality 
control samples. This indicates that the experiments were 
conducted consistently and that the spectra are of high qual-
ity. In contrast, the spectra in red are the low quality spectra 
detected by the correlation matrix and that need to be dis-
carded prior to data analysis. All of the low quality spectra 
are different from the high quality spectra in terms of the 
peak patterns. Furthermore, unique peak patterns do not 
exist among the low quality spectra.
Comparison of spectral quality before and after low quality  spectra are detected by the correlation matrix and discarded Figure 5
Comparison of spectral quality before and after low 
quality spectra are detected by the correlation 
matrix and discarded. The quality of spectra from biologi-
cal replicates of quality control samples is illustrated in the 
Pearson correlation matrix surfaces that were generated 
using the software DMVS 2.0 (Shenzhen Chipscreen Bio-
sciences, Ltd, Shenzhen, P. R. China, http://www.chip-
screen.com). The x and y axes represent spectra and the z-
axes indicate the values of Pearson correlation coefficients. 
The bright red color indicates very good correlation with val-
ues of R close to 1, and the green color indicates that a low 
correlation was observed between two spectra. (A) Correla-
tion matrix was applied to the dataset prior to quality con-
trol. Green valleys caused by several low quality spectra that 
had very low correlations to most of other spectra were 
detected. (B) After the low quality spectra were detected by 
the correlation matrix and discarded, the Pearson correla-
tion matrix surface became clear and very red, indicating that 
the majority of the correlations among all spectra are very 
high.BMC Bioinformatics 2005, 6(Suppl 2):S5
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the data analysis for identification of biomarkers. The
comparison of data sets before and after the low quality
spectra were discarded is shown as spectral correlation
matrix surface in Fig. 5. After the low quality spectra were
discarded (Fig. 5B) the correlation matrix surface is much
smoother, cleaner and bright in red compared to the sur-
face before those spectra were discarded (Fig. 5A).
In our study of identification of biomarkers for myeloma-
associated lytic bone disease, technical replicates were
used for quality control purpose to make the identifica-
tion of biomarkers and associated patterns reliable for
potential application in clinical diagnosis. Each serum
sample from a newly diagnosed myeloma patient was
placed on four adjacent spots of a chip for SELDI assays.
The four SELDI mass spectra should be very similar since
they are the replicates of the same sample. It was expected
that use of technical replicates could serve a QC purpose
to ensure all the spectra used in the data analysis were of
high quality. Integration of quality control prior to the
data analysis improves the quality of the predictive model
derived from the data set with respect to prediction accu-
racy, sensitivity, and specificity (result not reported here).
Here we show examples of the application of the correla-
tion matrix as a quality control tool for the technical rep-
licates used in our myeloma-associated lytic bone disease
study. To explain how to detect and discard low quality
spectrum, spectra from two patients X and Y, one with a
low quality spectrum and the other with all high quality
spectra were elected as examples. Table 1 lists the correla-
tion matrix of the four SELDI mass spectra obtained from
patient X, where high correlations among the four spectra
are observed with r greater than 0.97. This indicates con-
sistency between the four SELDI experiments such that
high quality spectra for biomarker identification should
be expected. In contrast, the correlation matrix indicated
low quality interspectrum correlation for patient Y (Table
2), where spectrum 3 has r < 0.9 compared with the other
three spectra. However, the other three spectra are well
correlated with r > 0.97. The ostensible single low quality
spectrum from patient Y suggests that experimental steps
were inconsistent, causing its corresponding spectrum to
poorly correlate. Accordingly, removal of spectrum 3
should result in more reliable biomarker identification.
Fig. 6A and Fig. 6B show plots of peak intensities for
patients X and Y, respectively. The similar and consistent
spectra for patient X are clearly evident, as are the dispa-
rate spectra for patient Y. The correlation matrix is thus an
effective metric for identifying the lower quality spectra.
Discussion
Recently, the scientific community has been using pro-
teomics to improve diagnostic/prognostic capability and
to study the underlying biological processes of diseases
and toxicology. Because of the complicated nature of the
SELDI-TOF MS ProteinChip analysis, stringent and relia-
ble quality assessment (QA) and quality control (QC)
methods and procedures undertaken prior to data analy-
sis are critical. The QA/QC analysis should assure that the
data has acceptable experimental variability and that
incongruent data that are not the result of biology are
screened out. Such assurance of data quality is a necessary
Table 1: Pearson correlation matrix of four spectra from patient X. Column "Mean" lists the average Pearson correlation coefficients 
of each spectrum to other spectra.
Spectrum 1 Spectrum 2 Spectrum 3 Spectrum 4 Mean
Spectrum 1 1 0.981669 0.966975 0.976304 0.981237
Spectrum 2 0.981669 1 0.982505 0.984483 0.987164
Spectrum 3 0.966975 0.982505 1 0.984252 0.983433
Spectrum 4 0.976304 0.984483 0.984252 1 0.98626
Table 2: Pearson correlation matrix of four spectra from patient Y. Column "Mean" lists the average Pearson correlation coefficients 
of each spectrum to other spectra.
Spectrum 1 Spectrum 2 Spectrum 3 Spectrum 4 Mean
Spectrum 1 1 0.974029 0.832734 0.973365 0.945032
Spectrum 2 0.974029 1 0.857734 0.979373 0.952784
Spectrum 3 0.832734 0.857734 1 0.897082 0.896888
Spectrum 4 0.973365 0.979373 0.897082 1 0.962455BMC Bioinformatics 2005, 6(Suppl 2):S5
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condition for identification of reliable biomarker expres-
sion patterns with clinical utility for diagnosis and prog-
nosis and for toxicity and safety assessment.
Two phases of quality assessment and quality control can
be applied in the workflow of SELDI-TOF MS ProteinChip
proteomic analysis. The first QA/QC phase is aimed at
examining and improving the experimental techniques to
produce quality data. This phase incorporates biological
and technical replicates to identify and quantify the sys-
tematic bias and noise in the experiments; the process
spans all experimental steps such as calibration of instru-
ments, proper sample preparation, and so forth. The
emphasis of this phase is on improving the quality of the
experiments.
The second QA/QC phase emphasises data analysis. Even
if stringent procedures are applied in the first phase, it is
difficult to guarantee that all spectra from the experiments
are of sufficient quality for subsequent data analysis. A
thorough quality assessment and quality control process
is required in order to ensure that only high quality data
are used. Low quality spectra need to be identified and
excluded.
A correlation matrix was found to be an effective means to
detect low quality spectra among the biological and tech-
nical replicates. Use of correlation matrix approach is
based on the assumption that spectra of biological and
technical replicates should be similar and well correlated,
and thus outlying spectra are of relatively lower quality
and significance. Our results suggest that inter-spectral
correlation coefficient values of R > .95 to .97 are attaina-
ble and representative figure-of-merit for quality data.
Spectra that are inconsistent with other replicates are
likely to have been compromised in one or more of the
many complex steps in SELDI, or by such factors as lack of
uniformity of the matrix material. While the correlation
matrix can identify likely anomalies and noisy spectra for
exclusion, it cannot indicate the source of the variability.
Even several phase one QC/QA methods such as using
pooled QC samples and using standard calibrant to cali-
brate the spectra were adopted in our studies to make the
experiments high quality, the correlation matrix still iden-
tified spectra should be excluded from analysis because of
low correlation with the other replicate spectra.
The liver cancer and liver toxicity study used 144 QC sam-
ples dispersed evenly across six Ciphergen bioprocessor
plates and different chips, and randomly located on dif-
ferent spots. The experiments were conducted on different
dates. No date effect was observed. The samples were col-
lected into heparinized tubes and stored at -80°C. The
period of storage for samples used in this study ranged
from several weeks to one year. The experiments and the
Examples of high and low quality spectra from technical repli- cates in myeloma-associated lytic bone disease study Figure 6
Examples of high and low quality spectra from tech-
nical replicates in myeloma-associated lytic bone dis-
ease study. The parallel coordinate plots of spectra of four 
replicates from sera of patients X and Y illustrate the differ-
ence between the high quality spectra and low quality spec-
tra. Each peak in the spectra of four replicates were drawn as 
four points and linked together by a line to show the relative 
trend. The y-axis is the intensity. (A) Four spectra from rep-
licates of serum of patient X showed very similar profiles and 
have a high degree of correlation to each other. (B) Spectra 
1, 2, and 4 from patient Y have similar profiles and therefore 
have high correlations to each other. But spectrum 3 has a 
different profile from the others. Since it is not consistent 
with the other replicates, it should be discarded prior to data 
analysis.BMC Bioinformatics 2005, 6(Suppl 2):S5
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quality assessment analysis showed that the samples were
very stable during sustained storage.
Conclusion
Application of new technologies such as SELDI-TOF MS
coupled with the ProteinChip for biomarker identifica-
tion requires a robust QA/QC assessment process. QA/QC
pre-processing is critical for discovery of biomarkers and
expression patterns that have potential use in clinical set-
tings, as well as in toxicity studies for safety assessment. In
this report, we described a method for monitoring the
quality of proteomics profiles from SELDI-TOF MS. The
results showed that the reproducibility of our SELDI
experiments studies of liver cancer and liver toxicity was
high with coefficients of variation less than 20% for five
common proteins across all 144 QC samples. In addition,
we found no systematic variability across plates or chips,
or spot locations. The quality assessment lent confidence
that the data obtained met requirements for biomarker
identification. To ensure that all data used in the data
analysis for the discovery of biomarkers are of high quality
with low noise, the low quality spectra should be identi-
fied and removed prior to data analysis. We developed a
method using a correlation matrix to identify the low
quality spectra observed in biological and technical repli-
cates. The correlation matrix approach was applied to the
liver cancer and toxicity study and the myeloma-associ-
ated lytic bone disease study to efficiently identify low
quality spectra prior to post-analysis.
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